Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

wbldb

Bellido, T.¹; Ali, A. A.¹; Gubrij, I.¹; Plotkin, L. I.¹; Fu, Q.¹; O’Brien, C. A.¹; Manolagas, S. C.¹; Jilka, R. L.¹

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis

Endocrinology. November 2005;146(11):4577-4583

©2005 The Endocrine Society

Affiliations

¹Division of Endocrinology and Metabolism, Center for Osteoporosis and Metabolic Bone Diseases, Central Arkansas Veterans Healthcare System, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205
Abstract

Both chronic excess of PTH, as in hyperparathyroidism, and intermittent elevation of PTH (by daily injections) increase the number of osteoblasts; albeit, the former is associated with bone catabolism and the later with bone anabolism. Intermittent PTH increases osteoblast number by attenuating osteoblast apoptosis, an effect that requires the transcription factor Runx2. However, chronic elevation of PTH does not affect osteoblast apoptosis because it stimulates the proteasomal degradation of Runx2. Here, we studied the effects of PTH on Sost, a Runx2 target gene expressed in osteocytes (former osteoblasts embedded in the bone matrix), which antagonizes the pro-osteoblastogenic actions of bone morphogenetic proteins and Wnts. We report that continuous infusion of PTH to mice for 4 d decreased Sost mRNA expression in vertebral bone by 80–90%. This effect was accompanied by a comparable reduction of sclerostin, the product of Sost, in osteocytes, as determined by quantitative immunoblot analysis of bone extracts and by immunostaining. In contrast, a single injection of PTH caused a transient 50% reduction in Sost mRNA at 2 h, but four daily injections had no effect on Sost mRNA or sclerostin. PTH strongly decreased Sost expression in osteocytes formed in primary cultures of neonatal murine calvaria cells as well as in osteocytic MLO-A5 cells, demonstrating a direct effect of PTH on this cell type. These results, together with evidence that sclerostin antagonizes bone morphogenetic proteins and Wnts, strongly suggest that suppression of Sost by PTH represents a novel mechanism for hormonal control of osteoblastogenesis mediated by osteocytes.
Links

DOI: 10.1210/en.2005-0239

PubMed: 16081646

WoS: 000232585200003
History

Received: 2005-02-28

Accepted: 2005-07-26

Online: 2005-08-04

Cited Works (12)

Year	Entry
2001	Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo P, Fu Y-H, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan JT. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot–containing protein. Am J Hum Genet. March 2001;68(3):577-589.
2005	Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. May 20, 2005;280(20):19883-19887.
2004	van Bezooijen RL, Roelen BAJ, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CWGM. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. March 15, 2004;199(6):805-814.
2001	Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den J Ende, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. March 1, 2001;10(5):537-543.
2004	Kalajzic I, Braut A, Guo D, Jiang X, Kronenberg MS, Mina M, Harris MA, Harris SE, Rowe DW. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone. July 2004;35(1):74-82.
2005	Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. August 2005;37(2):148-158.
1999	Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. August 1999;104(4):439-446.
2003	Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. January 2003;22(23):6267-6276.
1997	Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsent G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. May 30, 1997;89(5):747-754.
1993	Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. December 1993;14(6):690-709.
2001	Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. May 10, 2001;344(19):1434-1441.
2000	Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. April 2000;21(2):115-137.

Cited By (43)

Year	Entry
2020	Robling AG, Bonewald LF. The osteocyte: new insights. Annu Rev Physiol. 2020;82:485-506.
2018	Bajwa NM, Sanchez CP, Lindsey RC, Watt H, Mohan S. Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism. BMC Nephrol. February 2, 2018;19(1):24.
2007	Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. June 2007;40(6):1434-1446.
2012	Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. January 2012;50(1):209-217.
2017	Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. March 2017;96:29-37.
2020	Hariri H, Pellicelli M, St-Arnaud R. Nfil3, a target of the naca transcriptional coregulator, affects osteoblast and osteocyte gene expression differentially. Bone. December 2020;141:115624.
2021	Baroi S, Czernik PJ, Chougule A, Griffin PR, Lecka-Czernik B. PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss. Bone. June 2021;147:115913.
2022	Bouchard AL, Dsouza C, Julien C, Rummler M, Gaumond M-H, Cermakian N, Willie BM. Bone adaptation to mechanical loading in mice is affected by circadian rhythms. Bone. January 2022;154:116218.
2022	Koide M, Yamashita T, Nakamura K, Yasuda H, Udagawa N, Kobayashi Y. Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice. Bone. July 2022;160:116401.
2023	Kitase Y, Prideaux M. Targeting osteocytes vs osteoblasts. Bone. May 2023;170:116724.
2014	Bellido T. Osteocyte-driven bone remodeling. Calcif Tiss Int. January 2014;94(1):25-34.
2021	Carrillo-López N, Martínez-Arias L, Fernández-Villabrille S, Ruiz-Torres MP, Dusso A, Cannata-Andía JB, Naves-Díaz M, Panizo S; European Renal Osteodystrophy (EUROD) Workgroup. Role of the RANK/RANKL/OPG and Wnt/β-catenin systems in CKD bone and cardiovascular disorders. Calcif Tiss Int. April 2021;108(4):439-451.
2010	Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. June 2010;31(3):266-300.
2013	Dallas SL, Prideaux M, Bonewald LF. The osteocyte: an endocrine cell … and more. Endocr Rev. October 2013;34(4):658-690.
2008	Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. February 29, 2008;283(9):5866-5875.
2015	Spatz JM, Wein MN, Gooi JH, Qu Y, Garr JL, Liu S, Barry KJ, Uda Y, Lai F, Dedic C, Balcells-Camps M, Kronenberg HM, Babij P, Pajevic PD. The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem. July 3, 2015;290(27):16744-16758.
2010	Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. February 2010;25(2):178-189.
2011	Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229-238.
2018	Ansari N, Ho PWM, Crimeen-Irwin B, Poulton IJ, Brunt AR, Forwood MR, Pajevic PD, Gooi JH, Martin TJ, Sims NA. Autocrine and paracrine regulation of the murine skeleton by osteocyte‐derived parathyroid hormone‐related protein. J Bone Miner Res. January 2018;33(1):137-153.
2020	Noda H, Guo J, Khatri A, Dean T, Reyes M, Armanini M, Brooks DJ, Martins JS, Schipani E, Bouxsein ML, Demay MB, Potts JT Jr, Jüppner H, Gardella TJ. An inverse agonist ligand of the PTH receptor partially rescues skeletal defects in a mouse model of Jansen's metaphyseal chondrodysplasia. J Bone Miner Res. March 2020;35(3):540-549.
2020	Zhao G, Kim EW, Jiang J, Bhoot C, Charles KR, Baek J, Mohan S, Adams JS, Tetradis S, Lyons KM. CCN1/Cyr61 is required in osteoblasts for responsiveness to the anabolic activity of PTH. J Bone Miner Res. November 2020;35(11):2289-2300.
2021	Balani DH, Trinh S, Xu M, Kronenberg HM. Sclerostin antibody administration increases the numbers of Sox9creER+ skeletal precursors and their progeny. J Bone Miner Res. April 2021;36(4):757-767.
2022	Treyball A, Bergeron AC, Brooks DJ, Langlais AL, Hashmi H, Nagano K, Barlow D, Neilson RJ, Roy TA, Nevola KT, Houseknecht KL, Baron R, Bouxsein ML, Guntur AR, Motyl KJ. Propranolol promotes bone formation and limits resorption through novel mechanisms during anabolic parathyroid hormone treatment in female C57BL/6J mice. J Bone Miner Res. May 2022;37(5):954-971.
2022	Damrath JG, Moe SM, Wallace JM. Calcimimetics alter periosteal and perilacunar bone matrix composition and material properties in early chronic kidney disease. J Bone Miner Res. July 2022;37(7):1297-1306.
2022	Kimura T, Panaroni C, Rankin EB, Purton LE, Wu JY. Loss of parathyroid hormone receptor signaling in osteoprogenitors is associated with accumulation of multiple hematopoietic lineages in the bone marrow. J Bone Miner Res. July 2022;37(7):1321-1334.
2011	Silva BC, Costa AG, Cusano NE, Kousteni S, Bilezikian JP. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest. November 2011;34(10):801-810.
2013	Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. February 2013;19(2):179-192.
2012	Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. January 2012;13(1):27-38.
2007	Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. NEJM. August 30, 2007;357(9):905-916.
2020	Koide M, Yamashita T, Murakami K, Uehara S, Nakamura K, Nakamura M, Matsushita M, Ara T, Yasuda H, Penninger JM, Takahashi N, Udagawa N, Kobayashi Y. Sclerostin expression in trabecular bone is downregulated by osteoclasts. Sci Rep. 2020;10:13751.
2015	Scully N. Differentiation of Osteoblasts to Osteocytes in 3D Type I Collagen Gels: A Novel Tool to Study Osteocyte Responses to Mechanical Loading [PhD thesis]. Cardiff, UK: Cardiff University; April 2015.
2020	Ziemian SN. The Roles of Subchondral Bone Mass, Stiffness, and Remodeling in Load-Induced Osteoarthritis Development [PhD thesis]. Ithaca, NY: Cornell University; August 2020.
2012	Ben-awadh AN. Contribution of RANKL Regulation to Bone Resorption Induced by PTH Receptor Activation in Osteocytes [Master's thesis]. Indianapolis, IN: Indiana University; June 2012.
2015	Newman CL. Assessing and Modifying Bone Quality in Chronic Kidney Disease [PhD thesis]. Indianapolis, IN: Indiana University; May 2015.
2017	Sato AY. Glucocorticoid Induced Osteoporosis and Mechanisms of Intervention [PhD thesis]. Indianapolis, IN: Indiana University; March 2017.
2019	Davis HM. Molecular Mechanisms Underlying Osteocyte Apoptosis and the Associated Osteoclastogenesis in Cx43-Deficiency and Aging [PhD thesis]. Indiana University – Purdue University Indianapolis (IUPUI); June 2019.
2015	Spatz JM. The Role of Osteocytes in Disuse and Microgravity-Induces Bone Loss [PhD thesis]. Cambridge, MA: Massachusetts Institute of Technology; September 2015.
2017	Morse AR. The Role of Wnt/β-Catenin Antagonists - Sclerostin and DKK1 - in Bone Homeostasis and Mechanotransduction [PhD thesis]. University of Sydney; 2017.
2013	Fowler TW. Activin Regulation of Osteoclast Formation, Motility, Function, and Survival [PhD thesis]. University of Arkansas for Medical Sciences; 2013.
2023	Zweifler L. The Role of Turnover and Inflammation in Bone [PhD thesis]. University of Michigan; 2023.
2016	Vrahna C. Investigating the Effects of Downstream Parathyroid Hormone (PTH) Targets on Bone Strength and Quality [PhD thesis]. Melbourne, Australia: The University of Melbourne; December 2016.
2011	Rieger R. Modélisation mécano-biologique par éléments finis de l'os trabéculaire: Des activités cellulaires au remodelage osseux [Mechano-Biological Modeling of Trabecular Bone by Finite Elements: From Cells’ Activities to Bone Remodeling] [PhD thesis]. University of Orleans; 2011.
2020	Hiebert B. The Development of a Cortical Bone Turnover Model: Parathyroid Hormone Effects in the Rabbit [Master's thesis]. University of Saskatchewan; July 2020.